Results 201 to 210 of about 7,245 (254)

Dual Role of the Spinal Endocannabinoid System in Response to Noxious Stimuli: Antinociceptive Pathways and Neuropathic Pain Mechanisms. [PDF]

Int J Mol Sci
Saldaña R, Carrascosa AJ, Torregrosa AB, Navarrete F, García-Gutiérrez MS, Manzanares J.   +5 more
europepmc   +1 more source

Impact of fertility treatments on headache disorders: a systematic review with an overview of treatment modalities. [PDF]

J Headache Pain
Hoehne CL, Lohner A, Salim Y, Terhart M, Andersen W, Angerhöfer C, Moltrecht R, Scheuerecker F, Maassen van den Brink A, Raffaelli B.   +9 more
europepmc   +1 more source

Why does FND mainly affect women? A consideration of gender imbalance in neuropsychiatric disease. [PDF]

Psychol Med
Bradlow R, Von Der Weid L, Zwickl S, Cheung A, Kanaan R.   +4 more
europepmc   +1 more source

Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management. [PDF]

Front Reprod Health
Guo ZQ.
europepmc   +1 more source

A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator [PDF]

Molecular Endocrinology, 2007
AbstractSelective progesterone receptor modulators (SPRMs) have been suggested as therapeutic agents for treatment of gynecological disorders. One such SPRM, asoprisnil, was recently in clinical trials for treatment of uterine fibroids and endometriosis.
Kevin P Madauss, Thomas B Stanley, Scott K Thompson   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Selective progesterone receptor modulators

Current Opinion in Obstetrics & Gynecology, 2014
Review of recent data from clinical trials and descriptions of endometrial morphology with administration of selective progesterone receptor modulators (SPRMs).Recent reports concerning administration of SPRMs, specifically the efficacy of ulipristal acetate in reducing fibroid size and rapid control of menstrual blood loss, have renewed clinical ...
Lucy H R, Whitaker, Alistair R W, Williams, Hilary O D, Critchley   +2 more
openaire   +2 more sources

Selective progesterone receptor modulators: an update

Expert Opinion on Pharmacotherapy, 2014
Several selective progesterone receptor modulators (SPRMs) show promise in several areas of medicine and this work has been summarized by us in 2008.Since the publication of our reviews, several developments have taken place in the field of reproductive medicine. The first is emergency contraception (EC).
BENAGIANO, Giuseppe, BASTIANELLI, Carlo, FARRIS, MANUELA, Ivo Brosens   +3 more
openaire   +3 more sources

Selective progesterone receptor modulators and reproductive health

Current Opinion in Endocrinology, Diabetes & Obesity, 2022
Purpose of review This review is intended to provide perspective on the history of selective progesterone receptor modulators (SPRMs) and progesterone antagonists, their current availability, therapeutic promise and safety concerns. Recent findings Despite keen interest in synthesis
openaire   +2 more sources

Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy

Steroids, 2003
Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and structurally related compounds represent a new class of progesterone receptor (PR) ligands that exhibit partial agonist and antagonist activities in vivo.
W Elger, Holger Hess-Stumpp
exaly   +3 more sources